LDS/Medical Tests/Familial Dysautonomia Genetic Mutation Analysis

Familial Dysautonomia Genetic Mutation Analysis

Familial Dysautonomia (FD) is an autosomal recessive disorder affecting one Ashkenazi Jewish ancestry individuals per 3,700. FD is a neurodegenerative disease characterized by hypotonia, absence of overflow tears, gastrointestinal dysfunction, altered temperature perception and sensitivity to pain, cardiovascular fluctuation, regressed gait, and a decreased life expectancy. Approximately 50% of FD patients die before 30 years of age.

Clinical testing strategies for FD include 1) confirmation testing to diagnose the disease, 2) presymptomatic, predictive testing of carrier status, and 3) prenatal testing to determine status of fetus with a family history of FD. Confirmation of disease status provides proper patient care and genetic information for at-risk relatives. Predictive testing determines genetic risk for individuals who have a family history of FD. Prenatal testing can be performed if both disease-causing alleles are identified in the family.

FD is caused by mutations in the IKBKAP gene located on chromosome 9, specifically the 9q31 region. The FD gene provides instructions for making the protein elongated complex protein; it is thought to create a chromatin structure for efficient mRNA elongation during transcription for multiple functions in the cell. Phenotypes are found to be associated with mutations in the IKBKAP gene.

FD is diagnosed by molecular genetic testing of the IKBKAP gene. The molecular basis of FD provides a key factor for detection and predictive patient impacts. Molecular testing such as targeted mutation analysis and DNA sequence analysis is used to determine the mutations. There are two mutations that account for more than 99% of mutant alleles for individuals of Ashkenazi Jewish ancestry. The first is c.2204+6T>C (formerly IVS20+6T>C) which is responsible for almost all occurrences of FD. The second mutant allele is c.2087G>C (p.R696P) which is rarely identified.

  • To identify disease-causing mutations in individuals affected with Familial Dysautonomia
  • To identify carriers in high risk ethnic groups or people with positive family history
  • Prenatal diagnosis of Familial Dysautonomia in known carrier parents

Heterozygous mutations c.2204 +6T>C (formerly IVS20 +6T>C) p.R696P indicate carrier status. Compound heterozygous mutation can develop disease; however, it is significant to screen a partner if a family is planned.

Negative for mutations analyzed
 

 

Mutations c.2204 +6T>C (formerly IVS20 +6T>C) p.R696P can be detected by: Polymerase chain reaction (PCR) amplification of the appropriate regions of the *IKBKAP* gene, allele-specific primer extension, and allelic discrimination using a fluorescent reporter molecule and color-coded microspheres, DNA sequencing analysis.

Whole blood EDTA. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Depends on the laboratory performing the test and patient care requirements. See Directory of Laboratories for methodologies and laboratory specific details.

1-2 weeks.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Obstet Gynecol. 2004;104:425–8. [PMID: 15292027]
  • Am J Med Genet A. 2003;118A:305–8. [PMID: 12687659]
  • Curr Opin Genet Dev. 2002;12:307–11. [PMID: 12076674]
  • Am J Med Genet. 2002;110:253–7. [PMID: 12116234]
  • Axelrod FB. Familial Dysautonomia. In: Robertson D, Low PA, Polinsky RJ (eds).
  • Primer on the Autonomic Nervous System. San Diego: Academic Press (1996). Pages 242-9.